摘要
目的 探讨血管内皮生长因子受体 3(VEGFR 3)与胃癌临床病理因素的关系。方法 应用免疫组织化学SP法测定胃癌及胃良性病变中VEGFR 3的表达 ,并以此来计数淋巴管密度。结果 淋巴管密度胃癌组为( 5 .80 0 0± 2 .3189)个 /× 2 0 0 ,胃良性病变组为 ( 2 .380 0± 0 .4 6 2 9)个 /× 2 0 0 (P =0 .0 0 0 ) ;有淋巴结转移者为 ( 6 .94 83± 1.5 831)个 /× 2 0 0 ,无淋巴结转移者为 ( 2 .772 7± 0 .4 2 89)个 /× 2 0 0 (P =0 .0 0 0 ) ;低分化组为( 7.6 818± 0 .982 9)个 /× 2 0 0 ,高 +中分化组为 ( 3.5 0 0 0± 1.0 2 82 )个 /× 2 0 0 (P =0 .0 0 0 ) ;pTNM分期Ⅰ +Ⅱ期为( 4 .2 917± 1.6 880 )个 /× 2 0 0 ,Ⅲ +Ⅳ期组为 ( 8.0 6 2 5± 0 .75 94 )个 /× 2 0 0 (P =0 .0 0 0 )。结论 胃癌淋巴管密度与其 pTNM分期。
Objective To investigate the relationship between vascular endothelial growth factor receptor 3 (VEGFR 3) and clinical pathology of gastric carcinoma(GC).Methods The expression of VEGFR 3 in 80 GCs and 20 gastric benign tissues (GBT) was detected by immunohistochemistry(SP), by which the density of lymphatic vessels (DLV) was calculated. Results The DLV in GC was (5.800 0±2.318 9)/×200, in GBT (2.380 0± 0.462 9) /×200( P =0.000); in GC with lymph node metastasis (6.948 3±1.583 1)/×200, without lymph node metastasis (2.772 7±0.428 9)/×200 ( P =0.000). In poorly differentiated type group, DLV was (7.681 8± 0.982 9) /×200, higher than that in moderately and highly differentiated type group 〔(3.500 0±1.028 2)/×200, P=0.000〕. DLV in pTNM Ⅰ+Ⅱ was (4.291 7±1.688 0)/×200, in Ⅲ+Ⅳ (8.062 5±0.759 4)/×200 ( P =0.000).Conclusion DLV shows positive relations with pTNM stage, differentiation and lymph node metastasis of GC.
出处
《中国普外基础与临床杂志》
CAS
2004年第4期341-343,共3页
Chinese Journal of Bases and Clinics In General Surgery
